United States Ovarian Cancer Therapeutics Market is expected to be dominated by Chemotherapy Segment through 2028
Increasing prevalence of ovarian
cancer is expected to drive the growth of the market in the forecast period,
2024-2028.
According to TechSci Research
report, “United States Ovarian Cancer Therapeutics Market - By
Region, Competition Forecast and Opportunities, 2018-2028,” the United
States Ovarian Cancer Therapeutics Market is anticipated to expand at a
remarkable rate in the forecast period, 2024-2028, owing to several drivers,
such as growing prevalence of ovarian cancer, aging population, and rising need
for new innovative treatments to treat ovarian cancer.
The United States ovarian cancer
therapeutics market is a rapidly growing market that encompasses a wide range
of treatment options, including chemotherapy, targeted therapies,
immunotherapy, and PARP inhibitors. Ovarian cancer is a challenging disease to
treat, and there is a significant need for more effective therapies that can
improve patient outcomes. In recent years, the US Food and Drug Administration
(FDA) has approved several new drugs for the treatment of ovarian cancer, which
has contributed to the growth of the market. Moreover, pharmaceutical companies
are investing heavily in research and development to develop new therapies that
can improve patient outcomes. With the increasing prevalence of ovarian cancer
and the aging population, the United States ovarian cancer therapeutics market
is expected to continue to grow in the coming years.
The United States market for
ovarian cancer therapeutics had been significantly impacted by the COVID-19
pandemic. Drug development and clinical testing were hampered by the pandemic,
which caused delays in the approval of new medicines. Additionally, the
pandemic had an impact on patient care, as numerous patients postponed or
cancelled appointments out of fear of contracting the virus. In addition, the
pandemic impacted the supply chain, resulting in a lack of medicines and other
medical supplies.
Browse over XX market data
Figures spread through 70 Pages and an
in-depth TOC on "United States Ovarian Cancer Therapeutics Market”
The United States Ovarian Cancer
Therapeutics Market can be segmented by drug class, tumor type, distribution
channel, region and competitive landscape.
In terms of tumor type, the
market can be divided into epithelial ovarian cancer, ovarian low malignant
potential tumor, germ cell tumor, and sex cord-stromal tumor. Due to its high
prevalence and incidence rates, epithelial ovarian cancer is anticipated to
dominate the market for ovarian cancer therapeutics in the United States in the
upcoming years. The majority of ovarian malignancies, or about 90% of cases,
are epithelial, making it the most prevalent kind. Additionally, the disease is
frequently discovered at a late stage, when it has already spread outside the
ovary, making treatment more difficult. There is a rising emphasis on creating
new therapeutics for epithelial ovarian cancer since there is a critical need
for efficient medications to enhance patient outcomes. Further boosting the
market's expansion, the FDA has approved a number of novel medications for the
treatment of epithelial ovarian cancer.
Based on the region, the market
can be classified into Northeast Region, Midwest Region, South Region, and West
Region. The Northeast region may have an advantage due to its high
concentration of cancer research institutes and pharmaceutical companies. The
region is home to several top-ranked cancer centers and research facilities,
including the Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer
Center. Additionally, several pharmaceutical companies with a focus on oncology
have a presence in the region, including Pfizer and Bristol-Myers Squibb. This
concentration of resources and experts in the Northeast region may result in
more significant advancements in ovarian cancer research and more extensive
access to innovative treatments for patients, leading to potential dominance in
the ovarian cancer therapeutics market.
Major companies operating in the
United States Ovarian Cancer Therapeutics Market include:
- AstraZeneca
- Genentech, Inc.
- GlaxoSmithKline PLC
- Janssen Biotech, Inc.
- Merck & Co., Inc.
- Novartis International AG
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
Download Free Sample Report
Customers can also request for
10% free customization on this report.
“The market for ovarian cancer
therapeutics in the United States is expanding quickly due to a number of
factors, including the rising incidence of ovarian cancer, an aging population,
and a critical need for efficient treatments. The market is characterized by a
number of trends, including the expanding use of immunotherapy, the discovery
of novel therapies like PARP inhibitors, and the growing emphasis on
personalized medicine. The market, however, also confronts several challenges,
such as the high cost of therapy, the absence of early diagnosis techniques,
and drug resistance. With many pharmaceutical companies investing extensively
in research and development to create novel treatments and protect their
intellectual property, clinical trials and patents also play a significant role
in the industry.” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based global management consulting firm.
“United States Ovarian Cancer
Therapeutics Market By Treatment (Chemotherapy, Radiation Therapy,
Immunotherapy, Hormonal Therapy, and Others), By Tumor Type (Epithelial Ovarian
Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, and Sex
Cord-Stromal Tumor), By Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, Online Pharmacies), By Region, Competition Forecast &
Opportunities, 2028,” has evaluated the future
growth potential of the United States Ovarian Cancer Therapeutics Market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in the United States Ovarian Cancer Therapeutics
Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com